<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><!-- InstanceBegin template="/Templates/main.dwt" codeOutsideHTMLIsLocked="false" -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" />
<!-- InstanceBeginEditable name="doctitle" -->
<title>VoterMedia.org: Pfizer: SEC Decision</title>
<!-- InstanceEndEditable --><!-- InstanceBeginEditable name="head" -->
<style type="text/css">
<!--
.style1 {font-size: 36px}
-->
</style>
<!-- InstanceEndEditable -->
<link href="../mainstyles.css" rel="stylesheet" type="text/css" />

<meta name="Keywords" content="voter-funded media, voter media, democracy, corporations, corporate governance, media reform, democratic reform, governance reform, corruption, Mark Latham" />
</head>

<body>
<table class="main" width="980" border="0" align="center" cellpadding="0" cellspacing="0">
  <tr>
    <td colspan="2" class="content"><!-- InstanceBeginEditable name="MainContent" -->
      <table width="976" border="0" cellpadding="15" cellspacing="0">
        <tr>
          <td width="824" valign="top">
		    <h3><strong>SEC No-Action Letter to Pfizer, February 22, 2000 </strong></h3>
		    <hr />
		    <blockquote>
              <p>February 22, 2000</p>
		      <p>&nbsp;</p>
		      <p><strong>Response of the Office of Chief Counsel<br />
              </strong><strong><u>Division of Corporation Finance</u></strong></p>
		      <p>Re: Pfizer, Inc.<br />
		        Incoming letter dated December 21, 1999</p>
		      <p>&nbsp;</p>
		      <p>The proposal would mandate that Pfizer hire a proxy      advisory firm, to be chosen by shareholder vote, to help      shareholders make voting decisions by providing them with an      analysis of the issues in proposals in Pfizer&rsquo;s proxy      materials for which Pfizer seeks shareholder approval.</p>
		      <p>There appears to be some basis for your view that Pfizer      may exclude the proposal under rule 14a-8(i)(8) as relating      to an election for membership on its board of directors.      Accordingly, we will not recommend enforcement action to the      Commission if Pfizer omits the proposal from its proxy      materials in reliance on rule 14a-8(i)(8). In reaching this      position, we have not found it necessary to address the      alternative bases for omission upon which Pfizer relies.</p>
		      <p>Sincerely,</p>
		      <p>Michael Ferraro,<br />
		        Attorney-Advisor</p>
	        </blockquote></td>
        </tr>
      </table>
    <!-- InstanceEndEditable --></td>
  </tr>
</table>
</body>
<!-- InstanceEnd --></html>
